Retatrutide (GLP-3RT) is a synthetic multi-agonist peptide developed for scientific research into metabolic regulation, energy balance, and endocrine signaling. It is designed to simultaneously interact with three key metabolic hormone receptors:

• Glucagon-like peptide-1 (GLP-1) receptor
• Glucose-dependent insulinotropic polypeptide (GIP) receptor
• Glucagon receptor

Because of this tri-agonist mechanism, Retatrutide is frequently studied in advanced metabolic research models exploring appetite signaling, glucose homeostasis, lipid metabolism, and energy expenditure pathways.

Retatrutide’s research relevance stems from its ability to engage multiple metabolic signaling pathways concurrently, a strategy designed to more closely mimic the body’s natural hormonal coordination involved in energy regulation.

In laboratory settings, this tri-receptor activity has been investigated for its effects on:

• Central appetite and satiety signaling
• Peripheral glucose metabolism
• Energy expenditure and thermogenesis
• Lipid mobilization pathways
• Hormonal cross-talk between gut, pancreas, liver, and brain

This multi-pathway approach distinguishes Retatrutide from single- or dual-agonist peptide systems and has made it a subject of interest in next-generation metabolic research.

Sequence: Not publicly disclosed
(Synthetic, engineered peptide derived from glucagon-family hormones with multiple strategic amino-acid substitutions and lipidation)
Molecular Formula: C187H291N51O60
Molecular Weight: Approx. 4260 g/mol (varies slightly depending on lipid side chain composition)
PubChem CID: Not assigned / not publicly available as a complete structure

1) What retatrutide is, mechanistically

Retatrutide is a single synthetic peptide engineered to act as a triple agonist at:

• GLP-1 receptor (satiety, gastric emptying, insulin secretion in a glucose-dependent manner)

• GIP receptor (incretin effects; may modulate appetite and adipose biology depending on context)

• Glucagon receptor (increases energy expenditure and lipid mobilization/oxidation, but can raise glucose—hence the importance of concurrent GLP-1/GIP activity)

This “triple” receptor profile is the scientific rationale for potentially larger effects on body weight, glycemia, and ectopic fat than GLP-1 alone. PubMed+2PubMed+2

2) Phase 2 obesity trial (major published efficacy/safety dataset)

Study type: Phase 2, randomized, double-blind, placebo-controlled
Population: Adults with obesity or overweight (without type 2 diabetes)
Duration: ~48 weeks of treatment

Key findings (high level):

• Large, dose-dependent weight loss vs placebo, with the highest doses producing the largest mean reductions. New England Journal of Medicine+2PubMed+2

• Adverse events were most commonly gastrointestinal (typical of incretin-based therapies), and tolerability was dose-related. PubMed+1

This NEJM paper is the cornerstone human dataset for obesity outcomes.

3) Phase 2 type 2 diabetes trial (glycemia + weight)

Study type: Phase 2, randomized, double-blind, parallel-group
Population: Adults with type 2 diabetes
Duration: ~36 weeks of treatment

Key findings:

• Clinically meaningful HbA1c reductions plus robust body-weight reductions, with a safety profile described as generally consistent with incretin-class effects. PubMed+1

• The authors note these Phase 2 data informed dose selection for Phase 3. PubMed

4) Liver fat / MASLD (NAFLD) substudy: imaging-quantified ectopic fat changes

A notable mechanistic/organ-targeted substudy examined metabolic dysfunction-associated steatotic liver disease (MASLD) using MRI-quantified liver fat.

Design: randomized, double-blind, placebo-controlled substudy embedded within the Phase 2 obesity trial (n≈98).
Key findings at 24 weeks:

• Large, dose-responsive relative liver fat reductions (e.g., ~−81% to −82% at higher doses vs ~0% placebo). Nature

• High proportions of participants achieving normal liver fat <5% at higher doses (reported up to the mid-80% range at week 24). Nature

• GI events were again the most common AEs in this substudy. Nature

This is one of the strongest published signals that the weight loss may be accompanied by meaningful reductions in ectopic fat, not just scale weight. Nature

5) Body composition (fat mass vs lean mass)

Because large weight loss raises the scientific question “how much is fat vs lean?”, a Phase 2 substudy in T2D evaluated body composition.

Key finding (summary):

• Retatrutide produced greater fat mass reduction vs placebo and dulaglutide, and the proportion of lean mass loss relative to total weight loss was reported as similar to other obesity treatments (i.e., not showing disproportionate lean loss in that analysis). PubMed+1

6) Phase 3 development: TRIUMPH program and outcomes being tested

Retatrutide has a broad Phase 3 program (“TRIUMPH”) designed to test not only weight loss but also obesity complications.

A published “rationale and design” paper describes:

• Four Phase 3 trials (including basket designs) across weight management, obstructive sleep apnea, and knee osteoarthritis, plus a trial in people with obesity and established cardiovascular disease. PMC

There is also an ongoing cardiovascular outcomes study listed on ClinicalTrials.gov evaluating major heart-related outcomes. ClinicalTrials.gov+1

Clinical Data:

GLP-3RT: Triple–Hormone-Receptor Agonist for Obesity — A Phase 2 Trial

GLP-3RT: A Study (LY3437943) in Participants With Obesity and Cardiovascular Disease (TRIUMPH-3)

GLP-3RT: Triple-Hormone-Receptor Agonist Study for Obesity – A Phase 2 Trial